Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Compound monograph · §3

IGF-1 LR3 — clinical evidence

Assessed outcomes with certainty ratings, contributing trials and the reasoning for each rating.

Document identifier
CEI-MN-029/3
Series
Compound monograph
Version
3.0
Published
18 Feb 2024
Last reviewed
18 Jun 2024
Next review
18 Jun 2026
Identifier
10.71829/cei.mono.29
Certainty
Very low
Cycle
2024 Q1

§3Clinical evidence

Assessed outcomes for IGF-1 LR3Point estimates with confidence intervals for each contributing study, plotted against the line of no effect.0.00.10.20.30.40.50.6Standardised direction and relative magnitude of the recorded effectIndicationEffect as recordedGH axis0 trials · Very lowNo randomised human evidence identified…Lean-mass preservation0 trials · Very lowNo randomised human evidence identified…
Moderate or high certaintyLow or very low certainty
Figure 3. Illustrative. Assessed outcomes plotted on a common standardised axis so that direction and relative magnitude can be compared at a glance. The estimates are not on a common natural scale and the intervals are the Institute's standardised representation of the reported precision, not the published confidence intervals. Published intervals appear in the per-indication extracts and in the text below.

§3.1Growth hormone deficiency and growth-hormone secretagogue pharmacology

Anchor outcome. Peak stimulated growth hormone.

Effect as recorded. No randomised human evidence identified for this analogue; —.[1,2]

Certainty. Very low certainty No trial of LR3 IGF-1 in any human population was located.

Contributing trials. None identified. The rating reflects an absence of controlled evidence rather than conflicting evidence.

Full evidence extract for growth hormone deficiency and growth-hormone secretagogue pharmacology · Indication assessment

§3.2Sarcopenia and lean-mass preservation during weight reduction

Anchor outcome. Change in appendicular lean mass by DXA.

Effect as recorded. No randomised human evidence identified for this analogue; —.[2,3]

Certainty. Very low certainty Native recombinant IGF-1 has an approved indication in severe primary IGF-1 deficiency; that evidence does not transfer to a binding-protein-evading analogue.

Contributing trials. None identified. The rating reflects an absence of controlled evidence rather than conflicting evidence.

Full evidence extract for sarcopenia and lean-mass preservation during weight reduction · Indication assessment

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH Harmonised Tripartite Guideline 1999;Step 4 version. identifier not held by the Institute
  2. United States Pharmacopeial Convention. General Chapter ⟨85⟩ Bacterial Endotoxins Test. United States Pharmacopeia — National Formulary (USP–NF) 2024;USP 2024 Issue 1. identifier not held by the Institute
  3. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.